- Intrexon (NASDAQ:XON) enters into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for RheoSwitch IL-12 in anti-tumor peripheral blood lymphocytes for potential use in cancer therapies. The term of the agreement is five years. Financial terms are not disclosed.
- The specific title of the CRADA is: "Development of NCI Proprietary Adoptive T Cell Therapies Using Autologous Peripheral Blood Cells with Naturally Occurring Endogenous Anti-Tumor Activity that are Genetically Modified Using Retroviral Vectors Encoding Intrexon Proprietary Controlled IL-12, for Use in the Immunotherapy of Patients with Metastatic Cancer."